How does HIVEX Treatment work?

HIVEX Treatment is an electro-magnetic treatment which targets proteins in the HIV virus

This is a diagram of the virus:

These clips explain how the virus infects other cells and reproduces:

http://www.sumanasinc.com/webcontent/animations/content/hiv.html

http://www.youtube.com/watch?v=RO8MP3wMvqg

The HIVEX   Treatment is designed to attack the HIV virus on three fronts simultaneously:

•  
  • Front 1: that region of the virus (GP 120) which attaches to the host cell, e.g. a CD4 lymphocyte, preventing the HIV to attach itself and start its destructive work    
  • Front 2: the pro-viral proteins which are produced once HIV has entered the host cell's nucleus, which normally would be new virulent HIV proteins, rendering them harmless.
  • Front 3: the material (envelope protein) which makes up the HIV virus wall, to impede the ability of new virus to leave the host cell.

HIVEX creates its electro-magnetic field in the following manner:

Selected HIV specific proteins (GP120, pro-viral proteins, envelope protein) are cultured so that there are millions of them. In treatment, a sample of these proteins is exposed to a broad white noise spectrum. As the proteins start to vibrate, the device picks up the weak signals and amplifies them, causing stronger vibration. The vibrations increase, feedback occurs, and is amplified many times over by HIVEX equipment. When the feedback resonance has developed sufficiently, the resulting spectral field, (“fingerprint”), becomes highly defined and therefore suitable for patients to be introduced into it.

The fingerprint now causes resonance of equivalent proteins in the virus within patients; that eventually effectively disables the  virus . Because the resonance is specific to the proteins chosen it is unlikely to affect anything else within the patient – no serious or long-term side effects have been observed – nothing more than occasional short-term headaches, dizziness or tingling.

The HIVEX Treatment targets the virus’s docking proteins, interrupts transcription and stops budding off, as shown here.  The viral cells remain in the body but can no longer damage – they can no longer  cause the death of other cells.  

This clip shows the way in which we believe the HIVEX treatment stops the HIV virus from docking onto host cells.

The HIVEX EMF Treatment reduces the rate of cell death, or “apoptosis” in an HIV infected person.”Apoptosis” is also called “programmed cell death” and is the name given to the process by which our cells die over time. In a healthy body, around 2 ½ - 5% of cells are dying and being replaced at any time.  But patients with HIV have higher than normal levels of apoptosis, rising from the normal level of 2 ½ - 5% or so at the time of HIV infection, to 40% or 50%. 

It is because the virus causes normal healthy, immune system cells to die that those with HIV lose T-cells, and their immune system becomes highly compromised. However, it was only in 1997 that it was realised that the drop in a patient’s T-cell levels correlated with the rise in their rate of apoptosis. In other words, measuring a patient’s rate of apoptosis may give a more accurate indication of disease progression than measuring viral load.

If a treatment can get the rate of apoptosis down, irrespective of whether or not it affects CD4 count, the patient should do better. Research into apoptosis has increased significantly in the last decade, but real awareness of its importance is only just coming into the public domain. Many patients with HIV still don’t know about the importance of the rate of apoptosis in disease progression – and they don’t know what their own rate is.

¹From Perry, et al., Microbial Life, First Edition, published by Sinauer Associates